Lightbulb icon

ECLIPSE PV (NCT05481151): a Phase 3b, randomized, open-label, parallel-group, multicenter study to evaluate the efficacy and safety of two dosing regimens of ropeginterferon alfa-2b-njft (an accelerated titrated dosing versus the current recommended dosing) for adult patients with polycythemia vera (PV).1,2

Ropeginterferon alfa-2b-njft is currently approved by the FDA for the treatment of PV.1

PharmaEssentia is the sponsor of the ECLIPSE PV study.1

Now recruiting: Phase 3b1,2

DNA strand graphic